Skip to content

Effect of Ayurvedic formulation- AYU-EDRF-12 in high blood pressure

Clinical evaluation of AYU-EDRF-12 in Hypertension - -

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/10/037288
Enrollment
140
Registered
2021-10-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

None listed

Sponsors

LMRC Pune
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All individual systolic blood pressure between 140 and 170 mm Hg All individual diastolic blood pressure between 90 and 110 mm Hg

Exclusion criteria

Exclusion criteria: Patients with Chronic Kidney disease Patients under psychiatry medicines.

Design outcomes

Primary

MeasureTime frame
Reduction in the blood pressure from the baseline, four weeks, eight weeks and 12 weeks. Prevent possible fall in Quality of life due to hypertension. Avoid adverse events from complications of hypertension.Timepoint: Both arms: fIRST ARM: Three months with intervention Second arm: Three months with Telmesartan 20 mg OD. First follow up- After four weeks Second follow up: After eight weeks Third follow up: After 12 weeks

Secondary

MeasureTime frame
Prevent myocardial infarction, stroke, acute coronary syndrome, death from cardiovascular causes. Overcome the side effects and limitations from antihypertensive drugs. Publications from this study.Timepoint: Minimum two years from the start of recruitment

Countries

India

Contacts

Public ContactMr Srinivas B Pattar

Lokmanya Research Centre

ayurvedsavitur@yahoo.co.in9326167845

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026